{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:34:10Z","timestamp":1792856050770,"version":"4.5.0"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Prognostic factors in rheumatoid arthritis relate to several aspects, such as prediction of joint damage and loss of function or prediction of response to a particular therapy. For many decades it has been well established that high disease activity, especially exemplified by swollen joint counts and acute phase reactants, is associated with progression of joint damage. In addition, rheumatoid factor (RF) positive patients, but not patients with anti-citrullinated peptide antibodies (ACPA) are particularly prone to high disease activity and joint destruction. Newer studies have looked at molecular markers, but they have either not shown better results than those seen with the long-established ones or have not been sufficiently validated. Most recent insights suggest that high C-reactive protein levels may predict a particularly good response to IL-6 blockade, but not to other therapies, and that high RF-levels may be associated with better responses to Fc-free monoclonal antibodies than molecules containing an Fc-region. It is hoped, however, that with newer techniques and better insight into RA pathogenesis research may come up with even better molecular markers than currently available to predict responses to specific drugs in the not-too-distant future.<\/jats:p>","DOI":"10.1093\/rheumatology\/keae701","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T19:24:22Z","timestamp":1736623462000},"page":"ii3-ii8","source":"Crossref","is-referenced-by-count":14,"title":["Poor prognostic factors and unmet needs in rheumatoid arthritis"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4302-8877","authenticated-orcid":false,"given":"Josef S","family":"Smolen","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine 3, Medical University of Vienna , Vienna,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"key":"2025041108015523400_keae701-B1","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2025041108015523400_keae701-B2","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/j.immuni.2022.11.009","article-title":"The pathogenesis of rheumatoid arthritis","volume":"55","author":"Alivernini","year":"2022","journal-title":"Immunity"},{"key":"2025041108015523400_keae701-B3","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.2008.092668","article-title":"Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2025041108015523400_keae701-B4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-065X.2008.00626.x","article-title":"Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics","volume":"223","author":"Feldmann","year":"2008","journal-title":"Immunol Rev"},{"key":"2025041108015523400_keae701-B5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025041108015523400_keae701-B6","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ard.2008.090019","article-title":"Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and TNF-blockade","volume":"68","author":"Smolen","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2025041108015523400_keae701-B7","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1699-0463.1940.tb01475.x","article-title":"On the occurrence of a factor in human serum activating the specific agglutination of sheep blood corpuscles","volume":"17","author":"Waaler","year":"1939","journal-title":"Acta Pathol Microbiol Immunol Scand"},{"key":"2025041108015523400_keae701-B8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1084\/jem.108.1.105","article-title":"Interaction of the rheumatoid factor with antigen-antibody complexes and aggregated gamma globulin","volume":"108","author":"Edelman","year":"1958","journal-title":"J Exp Med"},{"key":"2025041108015523400_keae701-B9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.52.4.561","article-title":"Serological Reactions in Pneumonia with a Non-Protein Somatic Fraction of Pneumococcus","volume":"52","author":"Tillett","year":"1930","journal-title":"J Exp Med"},{"key":"2025041108015523400_keae701-B10","first-page":"224","article-title":"Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentrations of C-reactive protein and erythrocyte sedimentation rate","volume":"9","author":"Mallya","year":"1982","journal-title":"J Rheumatol"},{"key":"2025041108015523400_keae701-B11","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/S0140-6736(87)91672-2","article-title":"Long-term outcome of treating rheumatoid arthritis: results after 20 years","volume":"1","author":"Scott","year":"1987","journal-title":"Lancet"},{"key":"2025041108015523400_keae701-B12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/rheumatology\/31.8.519","article-title":"Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients","volume":"31","author":"Van der Heijde","year":"1992","journal-title":"Br J Rheumatol"},{"key":"2025041108015523400_keae701-B13","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/art.1780340707","article-title":"Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Results of a followup study","volume":"34","author":"van Zeben","year":"1991","journal-title":"Arthritis Rheum"},{"key":"2025041108015523400_keae701-B14","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/art.23439","article-title":"Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies","volume":"58","author":"de Vries-Bouwstra","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2025041108015523400_keae701-B15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s13075-015-0736-9","article-title":"Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials","volume":"17","author":"Aletaha","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2025041108015523400_keae701-B16","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/art.38307","article-title":"Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis","volume":"66","author":"Sokolove","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025041108015523400_keae701-B17","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1136\/annrheumdis-2013-204543","article-title":"IgM rheumatoid factor amplifies the inflammatory response of macrophages induced by the rheumatoid arthritis-specific immune complexes containing anticitrullinated protein antibodies","volume":"74","author":"Laurent","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025041108015523400_keae701-B18","first-page":"380","article-title":"Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors","author":"MM","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2025041108015523400_keae701-B19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.clim.2018.05.004","article-title":"Combination of anti-citrullinated protein antibodies and rheumatoid factor is associated with increased systemic inflammatory mediators and more rapid progression from preclinical to clinical rheumatoid arthritis","volume":"195","author":"Lingampalli","year":"2018","journal-title":"Clin Immunol"},{"key":"2025041108015523400_keae701-B20","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1136\/ard.2010.131201","article-title":"Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab","volume":"69","author":"Klarenbeek","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025041108015523400_keae701-B21","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/rheumatology\/kep155","article-title":"A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis","volume":"48","author":"Vastesaeger","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"2025041108015523400_keae701-B22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1136\/annrheumdis-2011-200395","article-title":"Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction","volume":"71","author":"Smolen","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2025041108015523400_keae701-B23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/annrheumdis-2012-201970","article-title":"Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients","volume":"72","author":"Aletaha","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025041108015523400_keae701-B24","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1136\/annrheumdis-2021-221323","article-title":"Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis","volume":"81","author":"Lopez-Romero","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025041108015523400_keae701-B25","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/art.37797","article-title":"Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis","volume":"65","author":"Binder","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025041108015523400_keae701-B26","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1136\/annrheumdis-2019-215751","article-title":"Synovial tissue signatures enhance clinical classification and prognostic\/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC)","volume":"78","author":"Lliso-Ribera","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025041108015523400_keae701-B27","doi-asserted-by":"crossref","first-page":"4897983","DOI":"10.1155\/2020\/4897983","article-title":"Synovial fluid cell proteomic analysis identifies upregulation of alpha-taxilin proteins in rheumatoid arthritis: a potential prognostic marker","volume":"2020","author":"Sarkar","year":"2020","journal-title":"J Immunol Res"},{"key":"2025041108015523400_keae701-B28","doi-asserted-by":"crossref","first-page":"865425","DOI":"10.3389\/fimmu.2022.865425","article-title":"Proteome profiling identifies serum biomarkers in rheumatoid arthritis","volume":"13","author":"Hu","year":"2022","journal-title":"Front Immunol"},{"key":"2025041108015523400_keae701-B29","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/14789450.2021.1908892","article-title":"Objective and noninvasive biochemical markers in rheumatoid arthritis: where are we and where are we going?","volume":"18","author":"Bay-Jensen","year":"2021","journal-title":"Expert Rev Proteomics"},{"key":"2025041108015523400_keae701-B30","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/art.39714","article-title":"Brief report: estimating disease activity using multi-biomarker disease activity scores in rheumatoid arthritis patients treated with abatacept or adalimumab","volume":"68","author":"Fleischmann","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025041108015523400_keae701-B31","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1016\/S0140-6736(16)31651-8","article-title":"Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"2025041108015523400_keae701-B32","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/art.37711","article-title":"Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study","volume":"65","author":"Weinblatt","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025041108015523400_keae701-B33","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1056\/NEJMoa2201302","article-title":"Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis","volume":"387","author":"Smolen","year":"2022","journal-title":"N Engl J Med"},{"key":"2025041108015523400_keae701-B34","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025041108015523400_keae701-B35","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"2025041108015523400_keae701-B36","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"key":"2025041108015523400_keae701-B37","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","article-title":"Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response","volume":"78","author":"Fleischmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025041108015523400_keae701-B38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025041108015523400_keae701-B39","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/ard-2022-223349","article-title":"Influence of active versus placebo control on treatment responses in randomised controlled trials in rheumatoid arthritis","volume":"82","author":"Kerschbaumer","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025041108015523400_keae701-B40","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and Management of Rheumatoid Arthritis: A Review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"2025041108015523400_keae701-B41","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrrheum.2012.23","article-title":"The pathogenesis of rheumatoid arthritis: new insights from old clinical data?","volume":"8","author":"Smolen","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"2025041108015523400_keae701-B42","first-page":"3818","article-title":"Interleukin-6 induction by tumor necrosis factor and interleukin-1 in human fibroblasts involves activation of a nuclear factor binding to a kappa B-like sequence","volume":"10","author":"Zhang","year":"1990","journal-title":"Mol Cell Biol"},{"key":"2025041108015523400_keae701-B43","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"key":"2025041108015523400_keae701-B44","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/ard.2007.074229","article-title":"Assessment of rituximab's immunomodulatory synovial effects (the ARISE trial). I: clinical and synovial biomarker results","volume":"67","author":"Kavanaugh","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2025041108015523400_keae701-B45","first-page":"620","article-title":"Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers","volume":"34","author":"Bresnihan","year":"2007","journal-title":"J Rheumatol"},{"key":"2025041108015523400_keae701-B46","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s40744-021-00330-y","article-title":"A molecular signature response classifier to predict inadequate response to tumor necrosis factor-alpha inhibitors: the NETWORK-004 prospective observational study","volume":"8","author":"Cohen","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2025041108015523400_keae701-B47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1089\/nsm.2020.0007","article-title":"Clinical validation of a blood-based predictive test for stratification of response to tumor necrosis factor inhibitor therapies in rheumatoid arthritis patients","volume":"3","author":"Mellors","year":"2020","journal-title":"Netw Syst Med"},{"key":"2025041108015523400_keae701-B48","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/14737159.2022.2020648","article-title":"Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-a inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis","volume":"22","author":"Strand","year":"2022","journal-title":"Expert Rev Mol Diagn"},{"key":"2025041108015523400_keae701-B49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40744-023-00618-1","article-title":"Decision impact analysis to measure the influence of molecular signature response classifier testing on treatment selection in rheumatoid arthritis","volume":"11","author":"Curtis","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2025041108015523400_keae701-B50","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrrheum.2015.8","article-title":"Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges","volume":"11","author":"Smolen","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"2025041108015523400_keae701-B51","doi-asserted-by":"crossref","first-page":"e0195123","DOI":"10.1371\/journal.pone.0195123","article-title":"Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"13","author":"Singh","year":"2018","journal-title":"PLoS One"},{"key":"2025041108015523400_keae701-B52","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/annrheumdis-2019-215987","article-title":"Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab","volume":"79","author":"Shafran","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025041108015523400_keae701-B53","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00296-021-05086-w","article-title":"Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study","volume":"42","author":"Nakayama","year":"2022","journal-title":"Rheumatol Int"},{"key":"2025041108015523400_keae701-B54","doi-asserted-by":"crossref","first-page":"e003975","DOI":"10.1136\/rmdopen-2023-003975","article-title":"Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study","volume":"10","author":"Lopez-Medina","year":"2024","journal-title":"RMD Open"},{"key":"2025041108015523400_keae701-B55","first-page":"999","article-title":"Influence of rheumatoid factor on serum drug levels of TNF inhibitors with different structures in rheumatoid arthritis","volume":"42","author":"Martinez-Feito","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"2025041108015523400_keae701-B56","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","article-title":"Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial","volume":"75","author":"Sokolove","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025041108015523400_keae701-B57","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1038\/s41598-024-56987-2","article-title":"Association of HLA-DRB1 locus with treatment response to abatacept or TNF inhibitors in patients with seropositive rheumatoid arthritis","volume":"14","author":"Cha","year":"2024","journal-title":"Sci Rep"},{"key":"2025041108015523400_keae701-B58","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2012-202361","article-title":"Forget personalised medicine and focus on abating disease activity","volume":"72","author":"Smolen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025041108015523400_keae701-B59","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/art.22943","article-title":"Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients","volume":"56","author":"Aletaha","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2025041108015523400_keae701-B60","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/annrheumdis-2015-207526","article-title":"Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update","volume":"75","author":"Stoffer","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025041108015523400_keae701-B61","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"SC","year":"2004","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae701\/61415074\/keae701.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/Supplement_2\/ii3\/61415074\/keae701.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/Supplement_2\/ii3\/61415074\/keae701.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T08:02:11Z","timestamp":1744358531000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/Supplement_2\/ii3\/7951893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,11]]},"references-count":61,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2025,1,11]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae701","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,1,11]]}}}